Pressures on US industry go beyond current price squeeze

With generics filling nine out of every 10 prescriptions in the US and achieving evergrowing savings that totalled US$265 billion in 2017 alone, onlookers could be forgiven for seeing the US generics industry as an unmitigated success. The US market is frequently used by other global territories as an aspirational example, demonstrating the opportunities and economies that are available when generics are utilised to their full extent and are able to comprehensively penetrate the market.